XML 26 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows-Indirect Method - BRL (R$)
R$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities from continuing operations      
Profit from continuing operations R$ 1,538,211 R$ 818,614 R$ 647,064
Adjustments to reconcile net income to cash provided by operating activities from continuing operations      
Share of profit (loss) of joint ventures and associates (12,181) 17,634 44,031
Amortization of contractual assets with customers – exclusive rights 504,907 282,521 289,436
Amortization of right-of-use assets 288,419 260,716 242,670
Depreciation and amortization 732,241 653,118 595,531
PIS and COFINS credits on depreciation 6,663 7,081 6,062
Interest and foreign exchange rate variations 1,625,987 1,133,882 533,926
Deferred income and social contribution taxes (296,459) (242,246) (234,244)
Current income and social contribution taxes 637,973 430,280 538,761
Loss on disposal of property, plant and equipment and intangible assets or assets write-off and other assets (322,190) (184,189) (85,455)
Reversal (loss) allowance for expected credit losses (49,989) (3,123) 15,281
Provision for losses with inventories 26,356 (826) 1,338
Provision for post-employment benefits 1,939 (2,393) (15,867)
Equity instrument granted 9,944 9,364 8,793
Provision of decarbonization – CBIO 638,542 161,281 124,287
Provision for tax, civil, and labor risks 61,039 93,328 21,582
Other provisions and adjustments 5,448 2,332 (1,912)
Cash flows from operations before changes in working capital 5,396,850 3,437,374 2,731,284
(Increase) decrease in assets      
Trade receivables and reseller financing (779,239) (956,779) 408,949
Inventories (1,004,819) (1,626,670) 108,136
Recoverable taxes (2,056,104) (826,133) (783,210)
Dividends received from joint ventures 146 1,005 4,836
Other assets (224,379) (19,392) (136,972)
Increase (decrease) in liabilities      
Trade payables and trade payables – reverse factoring 1,557,837 2,425,821 798,180
Salaries and related charges 130,586 63,066 15,644
Taxes payable (9,442) 11,733 22,925
Other liabilities 677,016 (55,099) (51,329)
Acquisition of CBIO (635,130) (176,837) (125,345)
Payments of contractual assets with customers – exclusivity rights (710,908) (420,261) (356,045)
Payments of contingencies (84,939) (24,351) (39,256)
Income and social contribution taxes paid (283,331) (230,036) (333,784)
Net cash provided by operating activities from continuing operations 1,974,144 1,603,441 2,264,013
Net cash provided by operating activities from discontinued operations 30,550 982,519 874,106
Net cash provided by operating activities 2,004,694 2,585,960 3,138,119
Cash flows from investing activities      
Financial investments, net of redemptions 1,567,962 1,863,053 (869,748)
Acquisition of property, plant, and equipment (929,236) (1,028,419) (750,618)
Acquisition of intangible assets (277,600) (237,488) (154,534)
Receipt of intercompany loan owed by Oxiteno S.A. to Ultrapar International 3,980,699 0 0
Cash provided by disposal of investments and property, plant and equipment 2,839,676 322,494 154,725
Capital increase in joint ventures (28,000) (25,700) (28,840)
Net cash consumed by subsidiaries acquisition (5,985) 0 0
Transactions with discontinued operations 987,895 0 0
Capital decrease in associates and redemption of shares 0 1,500 0
Initial direct costs of right-of-use assets (12,120) (14,905) 0
Receipt from related parties 0 2,334 0
Net cash provided (consumed) by investing activities from continuing operations 8,123,291 882,869 (1,649,015)
Net cash consumed by investing activities from discontinued operations (220,190) (158,733) (487,390)
Net cash provided (consumed) by investing activities 7,903,101 724,136 (2,136,405)
Loans and debentures      
Proceeds 1,519,580 1,383,611 3,387,161
Repayments (5,848,611) (2,426,222) (1,815,130)
Interest and derivatives paid (1,398,229) (733,791) (701,458)
Payments of lease      
Principal (351,011) (304,975) (250,202)
Interest paid (6,868) (15,267) (5,705)
Dividends paid (638,280) (705,753) (284,767)
Proceeds of financial liabilities of customers 162,895 0 0
Payments of financial liabilities of customers (173,948) 0 0
Capital increase made by non-controlling interests and redemption of shares 21,682 0 0
Payment to related parties (18,926) (177) (2,548)
Net cash provided (consumed) by financing activities from continuing operations (6,731,716) (2,802,574) 327,351
Net cash consumed by financing activities from discontinued operations (179,025) (552,967) (919,684)
Net cash consumed by financing activities (6,910,741) (3,355,541) (592,333)
Effect of exchange rate changes on cash and cash equivalents in foreign currency - continuing operations (24,024) (4,547) 21,912
Effect of exchange rate changes on cash and cash equivalents in foreign currency - discontinued operations (19,316) 56,553 114,822
Increase in cash and cash equivalents - continuing operations 3,341,695 6,561 546,115
Decrease in cash and cash equivalents - discontinued operations (387,981) 0 0
Cash and cash equivalents at the beginning of the year - continuing operations 2,280,074 2,661,494 2,115,379
Cash and cash equivalents at the beginning of the year - discontinued operations 387,981 0 0
Cash and cash equivalents at the end of the year - continuing operations 5,621,769 2,280,074 2,661,494
Cash and cash equivalents at the end of the year - discontinued operations 0 387,981 0
Transactions without cash effect:      
Contingent consideration – subsidiaries purchase 89,640 0 0
Addition on right-of-use assets and leases payable 482,439 227,977 420,070
Movement without cash effect of escrow deposits and provision for tax, civil and labor risks 41,888 0 0
Addition on contractual assets with customers – exclusivity rights 63,061 269,725 193,040
Capital increase performed by non-controlling interests 13,519 0 0
Reversal fund - private pension 3,107 2,656 33,843
Issuance of shares related to the subscription warrants – indemnification – Extrafarma acquisition R$ 942 R$ 1,819 R$ 54,763